These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
11. Natalizumab in Multiple Sclerosis: Long-Term Management. Clerico M; Artusi CA; Liberto AD; Rolla S; Bardina V; Barbero P; Mercanti SF; Durelli L Int J Mol Sci; 2017 Apr; 18(5):. PubMed ID: 28468254 [TBL] [Abstract][Full Text] [Related]
12. Multiple sclerosis: current and emerging disease-modifying therapies and treatment strategies. Wingerchuk DM; Carter JL Mayo Clin Proc; 2014 Feb; 89(2):225-40. PubMed ID: 24485135 [TBL] [Abstract][Full Text] [Related]
13. Multiple sclerosis update: use of MRI for early diagnosis, disease monitoring and assessment of treatment related complications. Igra MS; Paling D; Wattjes MP; Connolly DJA; Hoggard N Br J Radiol; 2017 Jun; 90(1074):20160721. PubMed ID: 28362522 [TBL] [Abstract][Full Text] [Related]
14. Spanish consensus on the use of natalizumab (Tysabri®)-2013. Fernández O; García-Merino JA; Arroyo R; Álvarez-Cermeño JC; Izquierdo G; Saiz A; Olascoaga J; Rodríguez-Antigüedad A; Prieto JM; Oreja-Guevara C; Hernández MA; Moral E; Meca J; Montalbán X Neurologia; 2015 Jun; 30(5):302-14. PubMed ID: 24360652 [TBL] [Abstract][Full Text] [Related]
15. Natalizumab for relapsing remitting multiple sclerosis. Pucci E; Giuliani G; Solari A; Simi S; Minozzi S; Di Pietrantonj C; Galea I Cochrane Database Syst Rev; 2011 Oct; (10):CD007621. PubMed ID: 21975773 [TBL] [Abstract][Full Text] [Related]
16. Switching patients at high risk of PML from natalizumab to another disease-modifying therapy. Giovannoni G; Marta M; Davis A; Turner B; Gnanapavan S; Schmierer K Pract Neurol; 2016 Oct; 16(5):389-93. PubMed ID: 27114560 [TBL] [Abstract][Full Text] [Related]
17. Stratification and monitoring of natalizumab-associated progressive multifocal leukoencephalopathy risk: recommendations from an expert group. McGuigan C; Craner M; Guadagno J; Kapoor R; Mazibrada G; Molyneux P; Nicholas R; Palace J; Pearson OR; Rog D; Young CA J Neurol Neurosurg Psychiatry; 2016 Feb; 87(2):117-25. PubMed ID: 26492930 [TBL] [Abstract][Full Text] [Related]
18. Natalizumab and progressive multifocal leukoencephalopathy: migrating towards safe adhesion molecule therapy in multiple sclerosis. Bennett JL Neurol Res; 2006 Apr; 28(3):291-8. PubMed ID: 16687056 [TBL] [Abstract][Full Text] [Related]
19. Design of TRUST, a non-interventional, multicenter, 3-year prospective study investigating an integrated patient management approach in patients with relapsing-remitting multiple sclerosis treated with natalizumab. Ziemssen T; Gass A; Wuerfel J; Bayas A; Tackenberg B; Limmroth V; Linker R; Mäurer M; Haas J; Stangel M; Meergans M; Harlin O; Hartung HP BMC Neurol; 2016 Jul; 16():98. PubMed ID: 27405225 [TBL] [Abstract][Full Text] [Related]